Participants will take a daily film‑coated tablet for about 40 weeks and will attend regular clinic visits where blood samples are taken to measure HbA1c (a test that shows average blood sugar over the past few months), Fasting plasma glucose (blood sugar after not eating), and will record their own readings using self‑monitoring of blood glucose. Weight, systolic and diastolic blood pressure will also be checked. The study follows a double‑blind design, meaning neither the participants nor the researchers know which pill is being taken until the study ends.

The purpose of the study is to determine whether twice‑weekly dosing of the drug can lower protein loss in the urine compared with placebo. Participants will first receive the active medication in an open‑label phase, followed by a randomized, double‑blind phase where some receive the drug and others receive the placebo, with regular monitoring of kidney function and safety.

Throughout the trial, participants will have periodic clinic visits where urine samples are collected to calculate the urine protein to creatinine ratio and the urine albumin to creatinine ratio, both of which indicate the level of protein leakage. Blood tests will also be performed to assess the estimated Glomerular Filtration Rate, a standard measure of how well the kidneys are filtering waste. The study continues over several months to observe changes in these measurements and to ensure the treatment is safe.

The study is planned in two groups, and neither the participants nor the study team will know which treatment is given. After starting treatment, the medicine is taken for a period of time and then the study looks at changes in urine protein and kidney function over about 20 weeks. The study is designed to compare BI 764198 with placebo across the different kidney disease groups.

People in the study are assigned by chance to receive either orelabrutinib or placebo. The study is set up so that neither the participants nor the study doctors know which treatment is being given during the trial. Treatment is taken over time, and the study follows participants to see how their condition changes during the study period.

PPMS can affect walking, balance, hand use, and other body functions. Disability progression means a gradual increase in these problems. The study is designed to compare how often this worsening happens in the two groups.

The study is a Phase 3 trial, which means it is being done in a larger group of people to better understand how well the treatment works and how safe it is. People taking part are assigned by chance to receive either nipocalimab or placebo. The treatment is given over time, and the study team follows participants through the treatment period to observe how the disease changes.

The purpose of the study is to determine if BI 764198 is more effective than a placebo at reducing the amount of protein leaked into the urine. During the study, participants will take either the active medication or a placebo in the form of an oral film-coated tablet. The treatment period lasts for 104 weeks, and the process is double-blind, meaning neither the participants nor the researchers know which treatment is being administered during the trial.

The purpose of the study is to see if etrasimod can help children reach clinical remission, a state where the symptoms of the disease are significantly reduced or disappear. During the study, participants will receive the medication in the form of tablets or granules taken by mouth. Over a period of 52 weeks, the way the body processes the medicine and any side effects will be monitored. Medical professionals will also check for changes in growth and physical development to ensure the treatment is safe for younger patients.

During the course of this research, participants will receive regular doses of the study drug to observe how it affects the body over an extended period. Medical professionals will monitor various aspects of health, including vital signs such as blood pressure and heart rate, as well as electrocardiogram results, which are tests that record the electrical activity of the heart. Additionally, regular blood tests will be performed to check hematology and clinical chemistry, which are used to examine the components of the blood and the chemical balance in the body.

The purpose of this study is to show whether empasiprubart works better than human normal immunoglobulin in improving the ability to perform daily activities in adults with this nerve condition. During the study, participants will be randomly assigned to receive either empasiprubart or human normal immunoglobulin through a vein. The study uses a double-dummy design, which means that all participants will receive two infusions to ensure that neither the participants nor the doctors know which treatment is being given. The main assessment will happen at week 24, when doctors will measure changes in functional ability using a scoring system that evaluates arm and leg function.

Throughout the study, various measurements will be taken to assess how well participants can perform daily tasks, their muscle strength, their walking ability, and their overall quality of life. Grip strength will be measured regularly, and participants will complete questionnaires about their disability, fatigue, pain, and general health status. Blood samples will be taken to measure drug levels and to check for any immune responses to the treatment. Safety will be monitored by tracking any unwanted effects, changes in laboratory tests, heart rhythm recordings, and vital signs. The study will also look at how the treatments affect specific proteins in the blood that are involved in the immune response and nerve damage.

The purpose of the study is to see if empasiprubart can help improve the ability to perform daily activities compared to placebo. The study will also look at how safe the medication is and how well it is tolerated by people with this nerve condition. Researchers want to understand if this treatment can help reduce disability and improve quality of life for people living with this condition.

The study is divided into two parts and will last up to about two years for each person who takes part. During the study, empasiprubart will be given through a needle into a vein, which is called an infusion. People taking part will have regular visits where doctors will check their muscle strength, ability to perform daily tasks, grip strength, and overall well-being. The study will also measure various safety aspects including blood tests, heart function tests, and any side effects that may occur. Throughout the study, researchers will collect blood samples to measure the levels of the medication in the body and to see how the immune system responds to the treatment.

The purpose of this study is to find out if ziltivekimab works better than placebo in reducing the risk of death from heart and blood vessel problems and preventing heart failure events such as hospital stays or urgent visits for worsening heart failure. The study will also look at other health outcomes including the combined risk of death from heart problems, heart attacks, and strokes, as well as how the treatment affects kidney function, quality of life, and inflammation levels in the body. Quality of life will be measured using questionnaires that ask about symptoms and daily activities.

During the study, participants will receive monthly injections for up to 48 months. The study will track various health events including hospitalizations for heart failure, deaths, heart attacks, strokes, and changes in heart and kidney function. Blood tests will be done to measure inflammation markers like hs-CRP and heart stress markers like NT-proBNP. Heart function will be checked using echocardiography, which is an ultrasound test that creates pictures of the heart. The study will continue until enough information has been collected to determine whether ziltivekimab is effective in helping people with this type of heart failure and inflammation.

The study will test a medication called rimegepant sulfate (also known as PF-07899801), which belongs to a group of medicines called calcitonin gene-related peptide antagonists. This medicine comes as an orodispersible tablet that dissolves in the mouth and is taken by mouth. The purpose is to determine if rimegepant sulfate works better than placebo in preventing migraines in adolescents with chronic migraine.

The study will last several months and will have two parts. In the first part, participants will receive either rimegepant sulfate or placebo without knowing which one they are taking. After this initial phase, there will be an extended period where all participants will receive the active medication. Throughout the study, participants will need to keep track of their headache days and complete questionnaires about how migraines affect their daily activities.

The study aims to determine if SAR441566 combined with methotrexate works better than placebo with methotrexate in treating moderate to severe rheumatoid arthritis. The treatment will be given as tablets taken by mouth. The study will last for 12 weeks, during which participants will receive either the study medication or placebo along with their regular methotrexate treatment.

Throughout the study, doctors will monitor how well the treatment works and check for any side effects. They will measure improvements in joint symptoms and overall disease activity. Blood samples will be collected to measure the amount of study medication in the body. This research is conducted as a phase 2 study, which means it is part of the early stages of testing this new treatment.

The purpose of this research is to evaluate how safe and effective these medications are in treating moderate to severe rheumatoid arthritis, either when used alone or in combination. The medications will be tested in patients who have previously tried other treatments for their condition but still have active disease symptoms.

During the study, participants will receive their assigned treatment for 12 months. All patients will continue taking methotrexate, a standard medication for rheumatoid arthritis, throughout the study period. The study will monitor how well the treatments work by measuring improvements in joint symptoms and overall disease activity.

The study medication comes in the form of film-coated tablets that are taken by mouth once daily. The treatment period lasts up to 76 weeks, during which participants will receive either BI 1291583 at a dose of 2.5 mg or a matching placebo. This is part of what is called a Phase III study, which is one of the final stages of testing a new medication before it can be approved for general use.

Throughout the study, participants will be monitored for improvements in their condition, particularly focusing on how often they experience pulmonary exacerbations (sudden worsening of respiratory symptoms that require antibiotic treatment). The study will also track changes in breathing tests and how the treatment affects participants’ quality of life related to their respiratory symptoms.

The study will test whether a medication called vicadrostat (BI 690517) when used in combination with another medication called empagliflozin is better than empagliflozin alone (with placebo) for treating heart failure. The purpose of the study is to determine if this combination therapy can reduce the occurrence of cardiovascular death, hospitalizations for heart failure, or urgent heart failure visits.

Participants in this study will be randomly assigned to receive either the combination of vicadrostat and empagliflozin or empagliflozin with placebo. The study will track outcomes such as cardiovascular events and measure heart failure symptoms using a questionnaire. This is a double-blind study, which means neither the participants nor the researchers will know which treatment each participant is receiving during the study.

The main purpose of this research is to determine if empasiprubart is effective at improving muscle strength compared to intravenous immunoglobulin in people with Multifocal Motor Neuropathy. Both medications will be given through intravenous infusion, which means they are administered directly into a vein.

The study is divided into two parts. During the treatment period, participants will receive either empasiprubart or intravenous immunoglobulin along with their matching placebos. Throughout the study, doctors will measure changes in muscle strength and other aspects of the condition. The research team will also monitor the safety of the treatments and collect information about how well participants feel and function in their daily activities.

The purpose of the study is to see if ferric derisomaltose can help reduce the number of deaths related to heart problems and the number of times patients need to be hospitalized due to worsening heart failure. Participants in the study will be randomly assigned to receive either the iron treatment or no iron treatment. The study will monitor participants over a period of time to track their health outcomes, such as hospital visits and overall survival.

Throughout the study, researchers will collect information on various health indicators, including changes in heart failure symptoms and iron levels in the blood. The study aims to provide valuable insights into whether treating iron deficiency with ferric derisomaltose can improve the health and quality of life for people with Chronic Heart Failure.

The purpose of the study is to demonstrate the contraceptive effectiveness of the Levonorgestrel Vaginal Delivery System. Participants in the study will be randomly assigned to use either the vaginal delivery system or the oral tablet for nine cycles, each lasting 28 days. The study will compare how well each method prevents pregnancy and will also monitor any side effects or health changes experienced by participants.

Throughout the study, participants will be observed for any adverse events, changes in vital signs, and overall health through physical and gynecological examinations. The study will also assess the quality of life and satisfaction of participants using a questionnaire. The trial aims to provide valuable information on the effectiveness and safety of these contraceptive methods over the course of the study period.

Participants in the study will use the Levonorgestrel Vaginal Delivery System for thirteen 28-day cycles. Throughout the study, researchers will monitor the participants to assess the system’s ability to prevent pregnancy and to observe any side effects or changes in health. The study will also look at how the system affects the quality of life and satisfaction of the participants. Additionally, for younger participants, the study will explore any changes in bone health using a method called DXA, which is a type of scan that measures bone density.

The purpose of this study is to demonstrate the contraceptive efficacy of the Levonorgestrel Vaginal Delivery System. Participants will be observed for any adverse events, changes in vital signs, and other health indicators to ensure the safety and tolerability of the treatment. The study will provide valuable information on how well this contraceptive method works and its impact on users’ health and well-being.

The purpose of the study is to evaluate the effectiveness of Nipocalimab in improving the symptoms of Sjögren’s Disease. Participants in the study will receive either Nipocalimab or a placebo over a period of time. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results. The main goal is to observe any changes in the disease activity from the start of the study to the end, which is planned to last for several months.

Throughout the study, participants will be monitored regularly to assess their health and any changes in their condition. This will involve routine check-ups and tests to track the progress of the disease and the effects of the treatment. The study aims to provide valuable information on whether Nipocalimab can be an effective treatment option for those suffering from moderate to severe Sjögren’s Disease.

The purpose of the study is to evaluate how well the combination treatment works in improving lung function and controlling asthma symptoms in participants aged 12 years and older. Participants will be randomly assigned to receive either the combination treatment, one of the individual medications, or a placebo. The study will last for four weeks, during which participants will use the inhaler as directed and attend regular check-ups to monitor their progress. The study aims to see if the combination treatment can provide better control of asthma symptoms compared to the individual medications or placebo.

Throughout the study, participants will be monitored for any changes in their asthma symptoms and overall health. The study will also track any side effects that may occur. By the end of the study, researchers hope to gather valuable information on the effectiveness and safety of the combination treatment for managing asthma. This information could help improve treatment options for people living with asthma in the future.

The purpose of this study is to see if the new treatment combination can improve the overall survival of patients with this type of cancer compared to the standard treatment. Participants in the study will be randomly assigned to receive either the new treatment or the standard treatment. The study will monitor the participants over time to assess the effectiveness and safety of the treatments. The study will also look at other factors such as how long the treatments can keep the cancer from getting worse and the overall response of the cancer to the treatments.

This study is important because it aims to find better treatment options for patients with advanced biliary tract cancer, which is a challenging condition to treat. By participating in this study, researchers hope to gather valuable information that could lead to improved outcomes for patients in the future. The study is expected to continue for several years to ensure comprehensive data collection and analysis.

The purpose of the study is to determine if BMS-986365 is more effective than the other treatments in delaying the progression of the disease. Participants will be randomly assigned to receive either BMS-986365 or one of the other treatments. The study will monitor how long it takes for the cancer to worsen, as well as overall survival, which refers to how long participants live while taking the medication. The study will use imaging techniques like X-rays or CT/MRI scans to track the progression of the disease.

Participants in the study will include men aged 18 or older who have this specific type of prostate cancer that is worsening. They should have evidence of cancer spreading, visible on scans, and should have previously tried certain treatments for prostate cancer. The study will continue until 2029, with the goal of providing valuable information on the effectiveness of BMS-986365 compared to other available treatments.

The purpose of this study is to learn more about how these medications work in the body, as well as to check their safety and how well they are tolerated by the infants. The study will be conducted in two parts, where the infants will receive either a single dose or multiple doses of the medications. The medications will be given through an intravenous infusion, which means they will be delivered directly into the bloodstream through a vein. The study will monitor the infants closely to see how their bodies process the medications and to watch for any side effects or reactions.

Throughout the study, researchers will collect information on how the medications affect the infants’ infections and overall health. This includes checking the levels of the medications in the blood, observing any side effects, and assessing the infants’ recovery from the infections. The study aims to provide valuable information that could help improve the treatment of serious bacterial infections in very young children.

The purpose of the study is to assess how well frexalimab works compared to teriflunomide in reducing the frequency of relapses in participants with relapsing forms of multiple sclerosis. Participants will be randomly assigned to receive either frexalimab, teriflunomide, or a placebo. A placebo is a substance with no active medication, used to compare the effects of the actual drugs. The study will also involve the use of MRI scans, which are imaging tests that help visualize the brain and spinal cord, to monitor changes in the condition over time.

Throughout the study, participants will receive regular check-ups and monitoring to ensure their safety and to track the effectiveness of the treatments. The study will last for a period of time, during which participants will be closely observed for any changes in their condition, including the number of relapses and any side effects they may experience. The goal is to gather information that could lead to improved treatment options for people living with multiple sclerosis.

The purpose of the study is to evaluate how effective and safe Efgartigimod is for patients with Primary Sjögren’s Syndrome. Participants in the study will receive either Efgartigimod or a placebo through subcutaneous injections, which means the injection is given under the skin. The study will follow participants over a period to observe changes in their condition, particularly looking at the activity of the disease and any improvements in symptoms.

Throughout the study, researchers will monitor participants to assess the treatment’s impact on disease activity and overall safety. The study aims to provide valuable information on whether Efgartigimod can help manage symptoms and improve the quality of life for those living with Primary Sjögren’s Syndrome. The trial includes an open-label extension, meaning that after the initial phase, all participants may have the opportunity to receive Efgartigimod, allowing further observation of its long-term effects.

The study will test if taking a 40 mg tablet of deucrictibant daily can prevent or reduce the occurrence of swelling attacks compared to taking a placebo. For comparison purposes, some participants will also have access to icatibant, an already approved medication that is injected under the skin to treat acute attacks when they occur.

The treatment period will last 24 weeks, during which participants will take either deucrictibant or placebo tablets. Throughout the study, participants will need to keep track of any swelling attacks they experience and may use emergency treatment if needed. The study will monitor how well the medication works and check for any potential side effects through regular health assessments.

The purpose of this study is to evaluate the safety and effectiveness of Tozorakimab in helping patients recover from severe viral lung infections. Participants in the study will receive either the Tozorakimab treatment or a placebo, in addition to the standard care they are already receiving. The study will monitor the participants over a period of time to see how many days they are alive and free from needing intensive care or extra oxygen, as well as other health outcomes.

Throughout the study, researchers will collect information on various health measures, such as the number of days participants are alive and not in the intensive care unit, and the time it takes for them to recover enough to stop needing extra oxygen. The study aims to provide valuable insights into how Tozorakimab can help improve the health and recovery of patients with severe viral lung infections.

The purpose of this research is to evaluate how safe and effective deucrictibant extended-release tablets are when taken regularly to prevent HAE attacks. The medication will be given as a 40 mg oral tablet that patients take to help reduce the frequency and severity of swelling episodes.

This is a long-term study where participants will receive the study medication and be monitored for any side effects and changes in their condition. During the study, patients will continue to have access to their usual emergency medications for treating sudden HAE attacks. Participants will need to keep track of their symptoms and complete various questionnaires about their quality of life and how well the treatment is working for them.

Participants in the study will be randomly assigned to receive either the combination of PF-06821497 and enzalutamide or enzalutamide with a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the investigational medicine and who is receiving the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The study will last for a period of time, during which participants will take the medications orally in the form of capsules or tablets. Regular check-ups and assessments will be conducted to monitor the participants’ health and the progression of the cancer.

The main goal of the study is to determine if the combination of PF-06821497 and enzalutamide can extend the time before the cancer worsens compared to the use of enzalutamide with a placebo. The study will also look at other outcomes, such as overall survival and the time it takes for the cancer to start growing again. Participants’ experiences with pain and quality of life will also be assessed throughout the study. This research aims to provide valuable information that could lead to improved treatment options for men with metastatic castration-resistant prostate cancer.

The purpose of this research is to determine how well sonelokimab works compared to placebo in treating people with active psoriatic arthritis who have not previously used biological medications. The study will compare two different ways of giving sonelokimab against placebo treatment.

Participants will receive either sonelokimab injections or placebo for 16 weeks. The medication dose will be 60 milligrams, given every four weeks. Throughout the study, doctors will monitor the participants’ symptoms, particularly focusing on how their joint pain and inflammation respond to the treatment. The study will also track any changes in participants’ ability to perform daily activities and their overall well-being.

The purpose of the study is to determine if the combination of PF-06821497 and enzalutamide is more effective in prolonging the time patients live without their cancer getting worse, compared to enzalutamide or docetaxel alone. Participants in the study will be randomly assigned to receive either the combination of PF-06821497 and enzalutamide, enzalutamide alone, or docetaxel. The study will involve taking medications in the form of tablets or capsules, and for those receiving docetaxel, it will be administered as an infusion into a vein. The study will last for several weeks, and participants will have regular check-ups to monitor their health and the progress of their cancer.

Throughout the study, participants will be closely monitored for any changes in their condition and any side effects they may experience. The study aims to provide valuable information on the effectiveness and safety of the new treatment combination for men with metastatic castration-resistant prostate cancer who have previously been treated with another medication called abiraterone acetate. This research could potentially lead to new treatment options for patients with this challenging form of prostate cancer.

The purpose of the study is to see how well these treatments can reduce protein levels in the urine, which is a sign of kidney damage. Participants in the study will receive one of the treatments or a placebo and will be monitored over a period of time to assess changes in their condition. The study will also track any side effects or adverse reactions to the treatments.

Participants will be randomly assigned to receive either Frexalimab, SAR442970, Rilzabrutinib, or a placebo. The study will be conducted in a way that neither the participants nor the researchers know who is receiving which treatment, to ensure unbiased results. The trial aims to provide valuable information on the potential benefits and risks of these treatments for people with FSGS or MCD.

The purpose of this study is to determine how well these eye drops work in slowing down the progression of myopia in children over a three-year treatment period. The study will compare the effectiveness of OT-101 eye drops against a placebo solution that looks the same but contains no active medication.

During the study, participants will receive either the OT-101 eye drops or placebo drops. The drops will be administered through ophthalmic use (placed directly in the eyes). The treatment will continue for three years, with regular check-ups to monitor changes in vision. The study will measure how the eye drops affect the progression of nearsightedness using specialized eye examinations.

The purpose of this study is to monitor the long-term safety of Berotralstat in individuals who have previously participated in Berotralstat studies. Participants in this trial will continue to take Berotralstat over an extended period, allowing researchers to gather important information about its safety and any potential side effects. The study will provide ongoing access to Berotralstat for those who have been part of earlier clinical trials, ensuring they can continue their treatment while contributing to valuable research.

Throughout the study, participants will be monitored for any treatment-related side effects or serious adverse events. The trial will continue until another way to access the medication becomes available, or until the sponsor decides to stop the global development and commercialization of Berotralstat. This study aims to ensure that Berotralstat remains a safe and effective option for managing Hereditary Angioedema in the long term.

The purpose of the study is to evaluate the safety and effectiveness of these treatments. Participants will be randomly assigned to one of the treatment groups and will receive their assigned treatment for a period of up to 90 days. The study will monitor the participants’ health and the progression of their prostate cancer during this time. The trial aims to determine which treatment approach is most effective in managing the disease.

Throughout the study, participants will undergo regular check-ups and assessments to track their response to the treatment. The study will also compare the outcomes of the different treatment groups to understand the benefits and potential side effects of each approach. This research is important for improving treatment options for men with high-risk nonmetastatic prostate cancer.

The purpose of this study is to evaluate how well ofatumumab is tolerated and how safe it is when used over a long period. Participants in the study will receive ofatumumab as an injection under the skin once every four weeks. The study will monitor participants for any side effects or changes in their health, including any changes in their laboratory test results or vital signs. The study will also track the number of relapses participants experience and any changes in their level of disability over time.

Participants will be followed for up to 240 weeks, which is about 4.5 years, to gather comprehensive data on the long-term effects of ofatumumab. The study aims to provide valuable information on the potential benefits and risks of using ofatumumab for managing relapsing multiple sclerosis, helping to inform future treatment options for this condition.

Participants in the study will be randomly assigned to receive either the new drug BAY 3283142 or a placebo, in addition to their standard care. The study will last for 16 weeks, during which time the participants will take the medication orally. The researchers will monitor changes in the urine albumin-creatinine ratio, which is a measure used to assess kidney function. This will help determine the most effective dose of the new drug for future studies.

Throughout the study, participants will have regular check-ups to monitor their kidney function and overall health. The study aims to find the best dose of BAY 3283142 to help reduce albumin in the urine, which could potentially improve kidney health in people with chronic kidney disease. The results of this study will help guide further research and development of this treatment.